BME/IQ Speaker: Marios Giannakis, MD, PhD

Event Date/Time: 
November 14, 2018 - 11:00am to 12:00pm
Event Location: 
IQ Atrium (775 Woodlot Dr)
Marios Giannakis
Novel Targeted and Immune-based Therapies in Colorectal Cancer: from Discovery to Clinical Practice

Dr. Giannakis is a physician-scientist and faculty at the Dana-Farber Cancer Institute and Harvard Medical School. He completed his undergraduate education at the University of Toronto and pursued M.D./Ph.D degrees at Washington University in Saint Louis. His graduate work under the mentorship of Dr. Jeffrey Gordon investigated the role of Helicobacter pylori in gastric carcinogenesis. Dr. Giannakis subsequently did his Internal Medicine Residency at Brigham and Women’s Hospital in Boston and completed his Hematology/Oncology Fellowship at the Dana-Farber Cancer Institute. He was a postdoctoral fellow in the laboratory of Dr. Levi Garraway at the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard prior to becoming an independent translational and clinical investigator at the Dana-Farber and Harvard Medical School. Dr. Giannakis has numerous publications on the genomics, immunogenomics and integrative molecular epidemiology studies of colorectal cancer and is a young investigator on the Stand-Up to Cancer Colorectal Cancer Dream Team.

Research Interests:  Dr. Giannakis is interested in the development of novel therapies for patients with colorectal cancer. His group works on the genomics of colorectal cancer and performs functional studies in pre-clinical models with a focus on understanding novel mutations in Wnt-signaling genes and translating these findings into targeted therapies for molecularly defined subsets of colorectal tumors. He is also interested in developing novel immunotherapeutic approaches in this disease and study the interactions between cancer cells and the colorectal cancer microenvironment. Towards this end, we integrate the immunogenomics of colorectal cancer with pathologic and transcriptional measurements of immunity, both in large epidemiologic cohorts and in individual colorectal cancer patients undergoing therapy, in order to understand mechanisms of immune evasion and resistance. We recently have expanded our efforts to study the role of metabolism and the microbiome in colorectal cancer pathogenesis and response to therapies.


Join from PC, Mac, iOS or Android:
Or join by phone: +1 646 876 9923   /   Meeting ID: 740 946 330